Novomix 30 Penfill 100 IU Inj 3 ml Cartridge

Like any other medicine, Novomix 30 Penfill 100 IU Inj 3 ml Cartridge also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Infusion site reaction
  
• Headache
  
• Pain
  
• Nasopharyngitis (inflammation of the throat and nasal passages)
  
• Auto-antibody formation
  
• Allergic reaction
  
• Injection site reactions (pain, swelling, redness)
  
• Weight gain
  
• Hypoglycemia (low blood glucose level)

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Dosage of this injection determined by the doctor as per the type of disease and overall health condition of the patient.
• Correct way of injecting Novomix 30 Penfill 100 IU Inj 3 ml Cartridge under the skin teach by your healthcare provider.
• It should be taken 15 minutes before a meal in the case of type 1 diabetes or in type 2 diabetes take it within 20 minutes after or starting a meal.
• Do not stop the medication without doctor's advice.
  
  

• Novomix 30 Penfill 100 IU Inj 3 ml Cartridge is a combination of two drugs such as Insulin Aspart (30%) & Insulin Aspart Protamine (70%) as an active ingredient.
• It is a fast-acting insulin in which Insulin Aspart has a fast onset of action and on the other hand Insulin Aspart Protamine has a prolonged duration of action.
• Together both the composition of this medicine ensure rapid as well as consistent sugar control by facilitating the reuptake of sugar in muscle and fat cells and also suppressing the production of sugar in the liver.

• Kinoshita, H., Yasuda, M., Nagasawa, K., & Yakushiji, F. (2013). Protamine-containing insulins are strong risk factors, and human insulin analogues are possible risk factors for insulin autoantibody: case-control study. Endocrinology Studies, 3(1), e3.
  
• Hermansen, K., Bohl, M., & Schioldan, A. G. (2016). Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs, 76(1), 41-74.
  
• Nishimura, H., Iizuka, K., & Takeda, J. (2014). Protamine-containing insulin but not analog insulin and duration of insulin use are risk factors for the production of insulin autoantibodies in insulin-treated patients with diabetes mellitus. Endocrine Journal, 61(6), 635-640.
  
• Bretzel, R. G., Arnolds, S., Medding, J., & Linn, T. (2004). A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care, 27(5), 1023-1027.
  
• Jacobsen, L. V., Søgaard, B., & Riis, A. (2000). Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. European journal of clinical pharmacology, 56(5), 399-403.